In a phase 2a RSV human challenge trial in healthy adults (60 infected of 114 randomised), oral S-337395 30 mg and 300 mg once daily for 5 days cut viral load AUC by 64.87% and 88.94% vs placebo; 300 mg also reduced symptom scores by 78.15%. Well tolerated.
RCTn = 114
Byrne et al. Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection